The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: A 6-month analysis

BJU International

Volumn 96, Issue 4, 2005, Pages 566-571

  Annemans, Lieven ^a,c,f   Cleemput, Irina ^b   Lamotte, Mark ^c   McNeill, Alan ^d   Hargreave, Timothy ^e  

^a GHENT UNIVERSITY   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c HEDM   (Belgium)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f NONE   (Belgium)

Author keywords

blocker; Acute urinary retention; Alfuzosin; Cost; Prostatectomy; Trial without catheter

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ARTICLE; CALCULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG USE; HOSPITALIZATION; HUMAN; MALE; MODEL; MONEY; MONTE CARLO METHOD; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; UNITED KINGDOM; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; DECISION SUPPORT TECHNIQUES; DRUG COSTS; EMERGENCY TREATMENT; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PROSTATECTOMY; PROSTATIC HYPERPLASIA; QUINAZOLINES; URINARY RETENTION;

EID: 24044500300     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05685.x     Document Type: Article

References (20)

1. Choong S, Emberton M. Acute urinary retention. BJU Int 2000; 85: 186-201
2. Schulman CC. Long-term aspects of medical treatment of BPH. Eur Urol 2001; 40: 8-12
3. Jacobsen SJ, Jacobsen DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7
4. Taube M, Gajraj H. Trial without catheter following acute urinary retention of urine. Br J Urol 1989; 63: 180-2
5. Murray K, Massey A, Feneley RCL. Acute urinary retention - a urodynamic assessment. Br J Urol 1984; 56: 468-73
6. Mc Neill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 2004; 43: 325-32
7. McNeill SA, Daruwala PD, Mitchell IDC, Shearer MG, Hargreave TB. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled trial. BJU Int 1999; 84: 622-62
8. Djavan B, Shariat S, Musbah O, Roehrborn CG, Maberger M. Does prolonged catheter drainage improve the chance of recovering voluntary voiding after acute urinary retention? Eur Urol 1998; 33 (Suppl. 1): 110, A437
9. Pickard R, Emberton M, Neal DE, on behalf of the National Prostatectomy Audit Steering Group. The management of men with acute urinary retention. Br J Urol 1998; 81: 712-20
10. McNeill SA, Hargreave TB, Roehrborn CG and Members of the ALFAUR Study Group. Alfuzosin 10 mg once a day in the management of acute urinary retention: results of a double-blind placebo controlled study. Urology 2005; 65: 83-90
11. Breum L, Klarskov P, Munck LK, Nielsen TH, Nordestgaard AG. Significance of acute urinary retention due to infravesical obstruction. Scand J Urol Nephrol 1982; 16: 21-4
12. Klarskov P, Andersen JT, Asmussen CF et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention. Scand J Urol Nephrol 1987; 21: 23-8
13. McNeill SA, Rizvi S, Byrne DJ. Prostate size influences outcome after presentation with a first episode of acute urinary retention. BJU Int 2004; 94: 559-62
14. Lamotte M, Massaer K, Vranckx K, Annemans L. A cost analysis of alfuzosin in the management of acute urinary retention. Value Health 2003; 6: 703
15. Department of Health (England). Hospital Episode Statistics 2002/03. London: DoH, 2003
16. Manikandan R, Srirangam SJ, O'Reilly PH, Collins GN. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK, a national survey. BJU Int 2004; 93: 84-8
17. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy, immediate and postoperative complications. A co-operative study of 13 participating institutions evaluation of 3,885 patients. J Urol 1989; 141: 243-7
18. Cravens DD, Zweig S. Urinary catheter management. Am Fam Physician 2000; 2: 369-76
19. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003; 349: 2387-98
20. Cleemput I, Kesteloot K, De Geest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 2002; 59: 65-94